

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226003 A1

(51) International Patent Classification:

C07D 403/10 (2006.01) C07D 409/06 (2006.01)
C07D 235/26 (2006.01) C07D 413/10 (2006.01)
C07D 401/06 (2006.01) C07D 417/10 (2006.01)
C07D 401/08 (2006.01) C07D 419/10 (2006.01)
C07D 401/12 (2006.01) C07D 495/04 (2006.01)
C07D 401/14 (2006.01) A61K 31/4184 (2006.01)
C07D 403/06 (2006.01) A61P 35/00 (2006.01)
C07D 405/06 (2006.01) C07D 409/14 (2006.01)

(21) International Application Number:

PCT/US2021/030541

(22) International Filing Date:

04 May 2021 (04.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/020,614 06 May 2020 (06.05.2020) US

(71) Applicant: **MERCK SHARP & DOHME CORP.**
[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): **CASH, Brandon, D.**
[US/US]; 33 Avenue Louis Pasteur, Boston, Massachusetts
02115-5727 (US). **FU, Wenlang** [US/US]; 2000 Galloping
Hill Road, Kenilworth, New Jersey 07033 (US). **GIAM-
BASU, George Madalin** [US/US]; 33 Avenue Louis Pas-
teur, Boston, Massachusetts 02115-5727 (US). **HAIDLE,
Andrew, M.** [US/US]; 33 Avenue Louis Pasteur, Boston,
Massachusetts 02115-5727 (US). **HOPKINS, Brett, A.**
[US/US]; 10257 Terri Lane, Brownsburg, Indiana 46112
(US). **LARSEN, Matthew, A.** [US/US]; 220 7th Street,
Templeton, California 93465 (US). **LESBURG, Charles,
A.** [US/US]; 33 Avenue Louis Pasteur, Boston, Massachu-
setts 02115-5727 (US). **LIU, Ping** [US/US]; 33 Avenue
Louis Pasteur, Boston, Massachusetts 02115-5727 (US).
MCGOWAN, Meredith, A. [US/US]; 176 Hillside Street,
Apt. 1, Boston, Massachusetts 02120 (US). **PU, Qinglin**
[US/US]; 33 Avenue Louis Pasteur, Boston, Massachu-
setts 02115-5727 (US). **SANYAL, Sulagna** [US/US]; 33
Avenue Louis Pasteur, Boston, Massachusetts 02115-5727

(US). **SILIPHAIVANH, Phiang** [US/US]; 33 Avenue
Louis Pasteur, Boston, Massachusetts 02115-5727 (US).
WHITE, Catherine, M. [US/US]; 33 Avenue Louis Pas-
teur, Boston, Massachusetts 02115-5727 (US). **YAN, Xin**
[CN/US]; 33 Avenue Louis Pasteur, Boston, Massachusetts
02115-5727 (US).

(74) Common Representative: **MERCK SHARP & DOHME
CORP.**; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: IL4I1 INHIBITORS AND METHODS OF USE



(57) Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.



WO 2021/226003 A1